Skip to main content

Table 1 Demographic and clinical characteristics of the study groups

From: The antipyretic efficacy and safety of propacetamol compared with dexibuprofen in febrile children: a multicenter, randomized, double-blind, comparative, phase 3 clinical trial

Characteristics Study groups (n = 125) Control group (n = 138) p-value
Gender, male (%) 63 (50.4) 70 (50.7) 0.957
Age (years) 3.0 [0–14.0] 3.0 [0–13.0] 0.730
 0.5–1 year (%) 35 (28.0) 41 (29.7) 0.700
 2–5 years (%) 65 (52.0) 68 (49.3)
 6–10 years (%) 20 (16.0) 26 (18.8)
 11–14 years (%) 5 (4.0) 3 (2.2)
Weight (kg) 13.9 [7.4–88.0] 15.0 [7.5–51.0] 0.515
Baseline temperature (°C) 38.6 ± 0.5 38.7 ± 0.5 0.159
Laboratory test results (at admission)
 White blood cell count (× 103/μL) 9.7 [2.7–28.3] 9.6 [1.9–27.7] 0.555
 Neutrophil (%) 60.0 [7.7–91.0] 63.7 [16.9–95.0] 0.208
 Lymphocyte (%) 29.1 [4.0–86.8] 24.8 [2.0–73.2] 0.134
 Platelet (×103/μL) 246.0 [102.0–583.0] 251.0 [91.0–504.0] 0.824
 C-reactive protein (mg/μL) 1.68 [0.1–105.1] 2.33 [0.1–139.1] 0.486
  1. Results are presented as median [range] or as mean ± standard deviation or as a percentage (%)